Éric Halioua
Company: PDC*line Pharma
Job title: President & Chief Executive Officer
Seminars:
New Class of Antigen-Specific Cancer Active Immunotherapies Based on a Potent Presenting Cell Line (PDC*line) 5:30 pm
PDC*line is a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of plasmacytoid dendritic cells Presentation of the first results of the ongoing phase I/II clinical trial for NSCLC patients Initiation of a phase Ib clinical trial with a personalized neoantigen-based vaccine in CRC patientsRead more
day: Conference Day One
Panel Discussion: Personalized vs Off-the-shelf Cancer Vaccines: Evaluating the Advantages & Disadvantages for Better Clinical Efficacy 3:00 pm
Debating the feasibility of individualized cancer vaccines vs targeting shared neoantigens Highlighting successes in personalized cancer vaccines that prove clinical efficacy and viability Considering the future opportunities for cancer vaccines in personalized & off-the-shelf for positive patient responseRead more
day: Pre-Conference Focus Day